Reaffirming congressional support for the Taiwan Relations Act and longstanding bipartisan Taiwan policy.

This resolution expresses congressional support for the Taiwan Relations Act and longstanding bipartisan Taiwan policy. It is a house resolution, not a public law, and was referred to the House Committee on Foreign Affairs on May 12, 2026. The bill text reaffirms the six statutory elements of the TRA and the Six Assurances, but contains no authorization of appropriations, no procurement directives, and no change to existing law. It is an expression of the sense of Congress. Funding mechanism: $0. The bill does not authorize or appropriate any funds. Arms sales to Taiwan occur through Foreign Military Sales (FMS) and Direct Commercial Sales (DCS) processes governed by the TRA and the Arms Export Control Act, which are separate from this resolution. No new contracts or funding lines are created. Structural winners and losers: The reaffirmation is neutral for all defense primes. It maintains the policy environment that allows for deferred, case-by-case arms sales decisions. For LMT, RTX, NOC, and BA, existing Taiwan programs (e.g., HIMARS, Patriot, sensors, F-16s) are unaffected. No company gains a new competitive advantage or sees incremental revenue as a direct result of this resolution. Timeline: As a referred resolution, the next step is committee consideration. It may or may not receive a hearing or markup. House resolutions expressing the sense of Congress on foreign policy often pass by voice vote but carry no binding legal effect. There is no Senate companion bill. The legislative path is short but the outcome is uncertain; even passage would not alter spending. For retail investors, this event does not change the fundamental outlook for defense stocks tied to Taiwan. The Taiwan policy framework is mature and already priced in. No new revenue streams or contracts have been announced in connection with this resolution.